UBS analyst Peter Lennox-King raised his price target for General Electric (GE) to $13 from $12 and keeps a Buy rating on the shares. The stock closed yesterday up 6%, or 65c, to $10.82.

With net proceeds of $20.5B from the BioPharma unit sale to Danaher (DHR), $2.9B in cash from Wabtec (WAB), $3.8B in new Wabtec shares, and $13B in Baker Hughes (BHGE) shares, GE has assets "well beyond" the $30B of Industrial debt reduction targeted last month, Lennox-King tells investors in a research note. This comes while the company retains ownership of ~$3B in Healthcare EBITDA, adds the analyst, who now could even envision a scenario of year-end 2020 leverage of below two times.

As leverage concerns fade, Lennox-King expects investor focus to shift to GE's "fundamental turnaround."